The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
Open accessAbstract
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Self-citationRisk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Self-citationEarly Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Self-citationHippisley-Cox, J., Coupland, C., & Brindle, P. (2017) · BMJ · doi:10.1136/bmj.j2099 · Cited by 1,703
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citationCardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Self-citationMulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Self-citationCameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32616-2 · Cited by 1,035
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Self-citationScappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Self-citationHochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Self-citationPinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Self-citationTrastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Self-citationKy, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563
Self-citationLeft ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Self-citationPerez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443
Self-citationEvaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.05.013 · Cited by 422
Self-citationCardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S. S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 356
Self-citationSubclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
van der Pal, H. J., van Dalen, E. C., van Delden, E., van Dijk, I. W., Kok, W. E., Geskus, R. B., Sieswerda, E., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4730 · Cited by 320
Cardio-Oncology Services: rationale, organization, and implementation
Lancellotti, P., Suter, T. M., López-Fernández, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J.-L., Jerusalem, G., Moonen, M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy453 · Cited by 311
Self-citationKozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305
Ezaz, G., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 276
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., Etienne, G., Nicolini, F. E., le Coutre, P., Clark, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00080-2 · Cited by 265
Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer
Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., Smith, B. D., Hortobagyi, G. N., & Giordano, S. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7884 · Cited by 244
Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C.-E., McNeill, C., Woodman, R. C., Hochhaus, A., le Coutre, P. D., & Saglio, G. (2013) · Leukemia · doi:10.1038/leu.2013.69 · Cited by 216
Self-citationGuenancia, C., Lefebvre, A., Cardinale, D., Yu, A. F., Ladoire, S., Ghiringhelli, F., Zeller, M., Rochette, L., Cottin, Y., & Vergely, C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4846 · Cited by 210
Self-citationHall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 207
Self-citationDi Lorenzo, G., Autorino, R., Bruni, G., Cartenì, G., Ricevuto, E., Tudini, M., Ficorella, C., Romano, C., Aieta, M., Giordano, A., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp025 · Cited by 207
Hamnvik, O. R., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M., Kaymakcalan, M. D., & Williams, J. S. (2015) · Cancer · doi:10.1002/cncr.28972 · Cited by 203
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Touyz, R. M., & Herrmann, J. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0056-z · Cited by 198
Self-citationCornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00231 · Cited by 198
Self-citationExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A., & Verrill, M. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn728 · Cited by 196
Self-citationMincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8890 · Cited by 170
Zardavas, D., Suter, T. M., Van Veldhuisen, D. J., Steinseifer, J., Noe, J., Lauer, S., Al-Sakaff, N., Piccart-Gebhart, M. J., & de Azambuja, E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7916 · Cited by 164
Self-citationTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
Serrano, C., Cortés, J., De Mattos-Arruda, L., Bellet, M., Gómez, P., Saura, C., Pérez, J., Vidal, M., Muñoz-Couselo, E., Carreras, M. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr348 · Cited by 161
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer
Bhatia, N., dos Santos, M. H. H., Jones, L. W., Beckman, J. A., Penson, D. F., Morgans, A., & Moslehi, J. J. (2016) · Circulation · doi:10.1161/circulationaha.115.012519 · Cited by 156
Self-citationActivity and Outcomes of a Cardio-Oncology Service in the United Kingdom—A Five-Year Experience
Pareek, N., Cevallos, J., Moliner, P., Shah, M., Tan, L. L., Chambers, V., Baksi, A. J., Khattar, R. S., Sharma, R., Rosen, S. D., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1292 · Cited by 145
Self-citationClinical features of pulmonary arterial hypertension in patients receiving dasatinib
Shah, N. P., Wallis, N., Farber, H. W., Mauro, M. J., Wolf, R. A., Mattei, D. G., Guha, M., Réa, D., & Peacock, A. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24174 · Cited by 128
Self-citationXiao, Y., Yin, J., Wei, J., & Shang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087671 · Cited by 126
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
Tarantini, L., Cioffi, G., Gori, S., Tuccia, F., Boccardi, L., Bovelli, D., Lestuzzi, C., Maurea, N., Oliva, S., Russo, G., et al. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.10.015 · Cited by 116
Wang, L., Tan, T. C., Halpern, E. F., Neilan, T. G., Francis, S. A., Picard, M. H., Fei, H., Hochberg, E. P., Abramson, J. S., Weyman, A. E., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.04.064 · Cited by 109
Self-citationCardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Dahlén, T., Edgren, G., Lambe, M. P., Höglund, M., Björkholm, M., Sandin, F., Själander, A., Richter, J., Olsson‐Strömberg, U., Ohm, L., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2306 · Cited by 105
Ewer, M. S., Suter, T. M., Lenihan, D. J., Niculescu, L., Breazna, A., Demetri, G. D., & Motzer, R. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.013 · Cited by 93
Self-citationLenihan, D. J., Stevens, P. L., Massey, M., Plana, J. C., Araujo, D. M., Fanale, M. A., Fayad, L., Fisch, M. J., & Yeh, E. T. H. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.04.003 · Cited by 91
Self-citationGandaglia, G., Sun, M., Popa, I., Schiffmann, J., Abdollah, F., Trinh, Q., Fred Saad, C., Graefen, M., Briganti, A., Montorsi, F., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12732 · Cited by 89
Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.016 · Cited by 86
Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12677 · Cited by 83
Libourel, E. J., Sonneveld, P., van der Holt, B., de Maat, M. P. M., & Leebeek, F. W. G. (2010) · Blood · doi:10.1182/blood-2009-12-257519 · Cited by 78
Gianni, L., Dombernowsky, P., Sledge, G. W., Martin, M., Amadori, D., Arbuck, S. G., Ravdin, P. M., Brown, M., MESSINA, M. E., Tuck, D. P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011655503511 · Cited by 78
Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study
Guglin, M. E., Hartlage, G. R., Reynolds, C. A., Ren, C., & Patel, V. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.04.011 · Cited by 73
Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors
Salz, T., Zabor, E. C., Brown, P. D. N., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., Steingart, R. M., Vickers, A. J., Munksgaard, P. S., Oeffinger, K. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4211 · Cited by 66
Pazopanib versus Sunitinib in Renal Cancer
Motzer, R. J., McCann, L., & Deen, K. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1311795 · Cited by 65
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
Nowsheen, S., Aziz, K., Park, J. Y., Lerman, A., Villarraga, H. R., Ruddy, K. J., & Herrmann, J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008637 · Cited by 58
Self-citationGünaldı, M., Duman, B. B., Afşar, Ç. U., et al. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214567162 · Cited by 52
Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003889 · Cited by 43
Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
Aghel, N., Lipton, J. H., Atenafu, E. G., Kim, D. D. H., & Delgado, D. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.006 · Cited by 38
Adamo, V., Ricciardi, G. R. R., Adamo, B., Ferraro, G., Franchina, T., Rossello, R., Zanghì, M., Cicero, G., Rizzo, S., Caristi, N., et al. (2013) · Oncology · doi:10.1159/000353450 · Cited by 34
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Chen, J. H., Lenihan, D. J., Phillips, S. E., Harrell, S. L., & Cornell, R. F. (2017) · Cardio-Oncology · doi:10.1186/s40959-017-0023-9 · Cited by 26
Self-citationCastagnetti, F., Breccia, M., Gugliotta, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144949 · Cited by 22
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationLyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationShyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationPudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2017 · Cited by 357
Self-citation
Metadata
- Authors
- Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., Neilan, T. G., Belenkov, Y., Rosen, S. D., Iakobishvili, Z., Sverdlov, A. L., Hajjar, L. A., Macedo, A. V. S., Manisty, C., Ciardiello, F., Farmakis, D., de Boer, R. A., Skouri, H., Suter, T. M., Cardinale, D., Witteles, R. M., Fradley, M. G., Herrmann, J., Cornell, R. F., Wechelaker, A., Mauro, M. J., Milojkovic, D., de Lavallade, H., Ruschitzka, F., Coats, A. J. S., Seferovic, P. M., Chioncel, O., Thum, T., Bauersachs, J., Andres, M. S., Wright, D. J., López-Fernández, T., Plummer, C., & Lenihan, D.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-06
- Volume
- 22
- Issue
- 11
- Pages
- 1945-1960
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W3031292493
- Cited by
- 815
- References
- 83
- FWCI
- 53.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.